What’s inside
Launched in 2005, the Invesco Pharmaceuticals ETF holds a lean portfolio of 29 companies, focusing on established players in the healthcare sector. Its largest positions include Abbott Laboratories (NYSE:ABT) at 5.67%, AbbVie (NYSE:ABBV) at 5.48%, and Amgen (NASDAQ:AMGN) at 5.34%. The fund maintains 100% exposure to the healthcare sector and operates without any leverage or environmental, social, and governance (ESG) filters. This ETF has paid $1.06 per share over the trailing 12 months, which, on its recent ~$124.66 share price, works out to a 0.8% yield.
Launched just one year later in 2006, the State Street SPDR S&P Pharmaceuticals ETF provides broader exposure with 65 holdings, though it also concentrates 100% on the healthcare sector. Its top holdings include Crinetics Pharmaceuticals (NASDAQ:CRNX) at 3.69%, MBX Biosciences (NASDAQ:MBX) at 3.22%, and AtaiBeckley (NASDAQ:ATAI) at 2.88%. Because it tracks an equal-weighted index, it leans more into midsized companies and smaller innovators than its Invesco counterpart. This ETF has paid $0.34 per share over the trailing 12 months, which, on its recent ~$69.98 share price, works out to a 0.5% yield.
Source:
Liên Minh Bảo Hiến Mỹ Gốc Việt
Vietnamese American Conservative Alliance (VACA)
https://freedom-vaca.org/vaca-blog-tieng-viet-nam/
https://freedom-vaca.org/vaca-main-blog-english-articles/